Dexamethasone phosphate (DXM-PHO) is an ester which is quickly hydrolysed by the bovine and the dexamethasone (DXM) plasma half-life was 5.16 h. It has been demonstrated that 54 h after DXM-PHO injection, DXM concentrations were lower than 0.1 mglml.
INTRODUCTION
Dexamethasone (DXM) and dexamethasone esters (phenylpropionate, sodium-phosphate, isonicotinate) are among the most potent fluorinated synthetic glucocoritcoids widely used in human and veterinary practice for their anti-inflammatory, anti-allergic and anti-rheumatic properties. For several years, it has been known that these compounds have also been illicitly administered as 'hormones' to improve the phenotype of beef cattle at the end of the fattening period (1, 2) .
The accumulation of such molecules and their metabolites in organs and meat could represent a potential hazard for the consumer's health which is still difficult to evaluate. Investigations of residues (in plasma and urine) are not easy due to the many interfering compounds resulting from general metabolism of the animal. Moreover, other factors such as the misreading of the drug, the low quantities injected, the number of treatments, the delay between the injection and slaughtering and the nature of the treatment (intramuscular, intravenous, or others) can considerably affect the possibilities of detecting traces of these molecules. This paper describes the study, by radioimmunoassay (RIA), of the DXM sodium-phosphate (DXM-PHO) phannacoldnetics in young cattle. Plasma half-life of the DXM, liberated from the ester, and the period in which DXM is still detectable have been determined, In further investigations on DXM metabolism, tritiated DXM was administered to another bull. Pharmacokinetics of the total radioactivity (tritiated DXM + related tritiated compounds) have also been studied and recovery of radioactive compounds from the urine was assessed.
MATERIALS AND METHODS
Plasma DXM concentrations were determined by RIA following the method described by Lejeune-Lenain et ., 
Treatments and sampling
Decadron (0.1 mglkg body weight) was injected in the left jugular vein and the animals were catheterized in the right jugular vein to minimize disturbances during blood sampling. Blood samples (10 ml) were collected at frequent intervals on the first day, put into ice-cold heparinized tubes and inunediately centrifuged.
Animal 4 was injected first with 400 J.l.Ci of tritiated DXM and 9 days later with 483 J.l.Ci. Radioactive plasma and urine samples were directly transferred to scintillation vials. After addition of 10 ml of RESULTS AND DISCUSSION Experiment 1: DXM·PHO in plasma DXM plasma concentrations are shown in semilogarithmic plots (Fig. 1) . Maximum levels (> 700 ng DXM/ml plasma) occurred during the first 15 min following the administration. Pharmacokinetics I and IT (on total radioactivity) were determined with 27 and 25 values respectively (Fig. 2) . Maximum radioactivity levels in plasma occurred during the first 15 min following the two injections and the residual radioactivity was estimated at 0.09 IlCi (0.02% of 400 IlCi administered) just before the second injection.
For both pharmacokinetics, the radioactivity levels declined very slowly to become insignificant « 0.05 IlCi), 11 days after the second treatment During the first 24 h, the elapsed time to recover half of the radioactivity was 8.8 h for both injections. This value, higher than that obtained for DXM, is a global measurement involving tritiated DXM and other related tritiated compounds produced, particularly DXM metabolites. In addition to the two blood sampling periods (9 and 12 days), urine samples were also collected in order to estimate the radioactivity excreted daily (Fig. 3) .
The total cumulative radioactivity recovered in urine 216 h after the administration, was 36.4% (first injection) and 22.6% (second injection). The number and the identification of DXM metabolites will be reported later.
